Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology speak about the SABCS 2021 Abstract – OT1-13-01 HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases.
Erika P. Hamilton, MD @ErikaHamilton9 @SaraCannonDocs #SABCS #BreastCancer #Cancer #Research Phase II HER2CLIMB-04 Trial
